Compare IRWD & HSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRWD | HSTM |
|---|---|---|
| Founded | 1998 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 663.6M | 642.6M |
| IPO Year | 2009 | 1999 |
| Metric | IRWD | HSTM |
|---|---|---|
| Price | $4.82 | $23.08 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | $7.67 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 1.8M | 168.9K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 0.66% |
| EPS Growth | ★ 1400.00 | N/A |
| EPS | 0.15 | ★ 0.61 |
| Revenue | $298,276,000.00 | ★ $304,064,000.00 |
| Revenue This Year | $57.95 | $9.45 |
| Revenue Next Year | $4.39 | $5.12 |
| P/E Ratio | ★ $31.07 | $39.59 |
| Revenue Growth | ★ 8.88 | 4.26 |
| 52 Week Low | $0.55 | $19.50 |
| 52 Week High | $5.78 | $29.59 |
| Indicator | IRWD | HSTM |
|---|---|---|
| Relative Strength Index (RSI) | 67.86 | 61.69 |
| Support Level | $3.07 | $21.19 |
| Resistance Level | $5.67 | $23.16 |
| Average True Range (ATR) | 0.26 | 0.81 |
| MACD | 0.06 | 0.24 |
| Stochastic Oscillator | 94.83 | 67.61 |
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
HealthStream Inc provides workforce and provider solutions for healthcare organizations. Its reportable segments include Workforce Solutions and Provider Solutions. Workforce development solutions consist of SaaS, subscription-based products that are used by healthcare organizations. Its Provider Solutions products offer healthcare organizations software applications for administering and tracking provider credentialing, privileging, call center and enrollment activities. The company generates a majority of its revenue from Subscription Services.